Sun Na, Gao Pingping, Li Yanling, Yan Zexuan, Peng Zaihui, Zhang Yi, Han Fei, Qi Xiaowei
Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University, Chongqing, China.
Institute of Pathology and Southwest Cancer Center, Key Laboratory of the Ministry of Education, Southwest Hospital, Army Medical University, Chongqing, China.
Front Mol Biosci. 2021 Feb 11;8:619110. doi: 10.3389/fmolb.2021.619110. eCollection 2021.
Breast cancer is one of the most common cancers. Although the present molecular classification improves the treatment effect and prognosis of breast cancer, the heterogeneity of the molecular subtype remains very complex, and the applicability and effectiveness of treatment methods are still limited leading to poorer patient prognosis than expected. Further identification of more refined molecular typing based on gene expression profile will yield better understanding of the heterogeneity, improving treatment effects and prolonging prognosis of patients. Here, we downloaded the mRNA expression profiles and corresponding clinical data of patients with breast cancer from public databases and performed typical molecular typing using PAM50 (Prediction Analysis of Microarray 50) method. Comparative analyses were performed to screen the common and specific differentially expressed genes (DEGs) between cancer and corresponding para-cancerous tissues in each breast cancer subtype. The GO and KEGG analyses of the DEGs were performed to enrich the common and specific functional progress and signaling pathway involved in breast cancer subtypes. A total of 38 key common and specific DEGs were identified and selected based on the validated results, GO/KEGG enrichments, and the priority of expression, including four common DEGs and 34 specific DEGs in different subtypes. The prognostic value of these key common and specific DEGs was further analyzed to obtain useful potential markers in clinic. Finally, the potential roles and the specific prognostic values of the common and specific DEGs were speculated and summarized in total breast cancer and different subtype breast cancer based on the results of these analyses. The findings of our study provide the basis of more refined molecular typing of breast cancer, potential new therapeutic targets and prognostic markers for different breast cancer subtypes.
乳腺癌是最常见的癌症之一。尽管目前的分子分类改善了乳腺癌的治疗效果和预后，但分子亚型的异质性仍然非常复杂，治疗方法的适用性和有效性仍然有限，导致患者预后比预期更差。基于基因表达谱进一步鉴定更精细的分子分型将有助于更好地理解异质性，提高治疗效果并延长患者预后。在此，我们从公共数据库下载了乳腺癌患者的mRNA表达谱和相应的临床数据，并使用PAM50（微阵列50预测分析）方法进行典型分子分型。进行比较分析以筛选每种乳腺癌亚型中癌组织与相应癌旁组织之间的共同和特异性差异表达基因（DEG）。对DEG进行GO和KEGG分析，以富集参与乳腺癌亚型的共同和特定功能进程及信号通路。基于验证结果、GO/KEGG富集以及表达优先级，共鉴定并选择了38个关键的共同和特异性DEG，包括不同亚型中的4个共同DEG和34个特异性DEG。进一步分析这些关键共同和特异性DEG的预后价值，以获得临床上有用的潜在标志物。最后，根据这些分析结果，推测并总结了共同和特异性DEG在总乳腺癌和不同亚型乳腺癌中的潜在作用及具体预后价值。我们研究的结果为乳腺癌更精细的分子分型、不同乳腺癌亚型的潜在新治疗靶点和预后标志物提供了依据。
